Allogene Therapeutics Q2 2026 net loss narrows to $42.7 million from $50.9 million
Allogene Therapeutics reported a second-quarter 2026 net loss of $42.7 million, or $0.13 per share, compared with $50.9 million, or $0.23 per share, a year earlier. The company also reported $423.6 million in cash, cash equivalents and investments as of June 30, 2026, and said that cash should fund operations into 2029. The filing furnishes a press release that also gives an update on its pivotal ALPHA3 trial of cema-cel in large B-cell lymphoma, including an interim MRD clearance result and FDA designations.
Key points
- Second-quarter 2026 collaboration revenue from a related party was $4.6 million, versus none a year earlier.
- Net loss was $42.7 million for the quarter ended June 30, 2026, versus $50.9 million in the same quarter of 2025.
- Guidance: 2026 operating expense is expected to be about $165 million, and GAAP operating expenses about $225 million, excluding potential business development activity.
- In the interim analysis, 58.3% (7/12) of cema-cel arm patients achieved MRD negativity versus 16.7% (2/12) in the observation arm; the FDA granted RMAT and Fast Track designations in July.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.